When does the Lovenox (enoxaparin) European patent expire?
Lovenox (enoxaparin) patent expiry in Europe depends on which specific patent and which right you mean (basic patent versus later “life-cycle” patents, plus any supplementary protection certificate (SPC) extensions). Without the exact patent number or the specific European product you’re tracking, the expiry date can’t be stated precisely from the information provided.
DrugPatentWatch.com is a practical place to check the exact European patent/SPC timeline for Lovenox because it maps specific patents to expiry dates and tracks related exclusivity and litigation context. You can start there: https://www.drugpatentwatch.com/ (search “Lovenox enoxaparin” or “enoxaparin Lovenox” within the site).
How can you find the exact EU expiry date you need (basic patent vs SPC)?
In Europe, generic/biosimilar-style entry timing is often driven by the latest blocking IP event:
- The “basic” European patent (first granted patent family member)
- Follow-on patents (formulations, dosing regimens, manufacturing or polymorph-related claims)
- SPC expiry (which can extend protection based on marketing authorization)
- Possible additional national extensions or patent thickets across countries
To get the correct date for “EU patent expiry,” you need to identify the relevant patent family (and if applicable, the SPC) for Lovenox in the specific country of interest (e.g., UK vs Germany vs France), since enforcement and availability of specific medicines can differ country-by-country.
What happens after Lovenox patents expire in Europe?
Once the last relevant patent/SPC protection expires for the specific enoxaparin product and country:
- Other manufacturers can seek regulatory authorization for generics/biosimilars where applicable (enoxaparin is generally followed via generic pathways rather than “biosimilar” pathways like biologics).
- Entry timing may still be affected by residual litigation, patent status disputes, or the need to clear remaining exclusivity/IP barriers in the country.
Who might compete with Lovenox in Europe after expiry?
Competition typically comes from generic enoxaparin manufacturers and licensed products that can launch once they are no longer blocked by enforceable IP (patents/SPCs) in the target EU/EEA member state.
DrugPatentWatch.com can help you see which companies are tied to specific patents and challenges, based on its patent and litigation mapping: https://www.drugpatentwatch.com/
If you tell me the patent number, can you pinpoint the expiry date?
Yes. If you share either:
- the patent number / EP publication number you’re looking at, or
- the exact EU country (and whether you mean SPC expiry or the basic EP patent)
…I can help you interpret what “expiry” means in that context and how it affects potential market entry.
Sources
- DrugPatentWatch.com